We conducted a search for protein truncating variants conferring protection against inflammatory bowel disease exploiting knowledge of common variants associated with the same disease. We found that a protein truncating variant (rs36095412, p.R179X, genotyped in 11,148 ulcerative colitis patients and 295,446 controls, MAF = up to 0.78%) in RNF186, a single-exon ring finger E3 ligase with strong colonic expression, protects against ulcerative colitis (overall P = 6.89x10 -7 , odds ratio (OR) = 0.30). We further demonstrate that the truncated protein is expressed, suggesting the protective mechanism may reside in the loss of an interaction or function via mislocalization or loss of an essential protein element.
Abstract (3 sentences)
We conducted a search for protein truncating variants conferring protection against inflammatory bowel disease exploiting knowledge of common variants associated with the same disease. We found that a protein truncating variant (rs36095412, p.R179X, genotyped in 11,148 ulcerative colitis patients and 295,446 controls, MAF = up to 0.78%) in RNF186, a single-exon ring finger E3 ligase with strong colonic expression, protects against ulcerative colitis (overall P = 6.89x10 -7 , odds ratio (OR) = 0.30). We further demonstrate that the truncated protein is expressed, suggesting the protective mechanism may reside in the loss of an interaction or function via mislocalization or loss of an essential protein element.
Main
Motivation A total of 200 loci have been unequivocally implicated to the two common forms of inflammatory bowel diseases (IBD): Crohn's disease (CD) and ulcerative colitis (UC) 1, 2 . For these findings, like most GWAS results, it has proven challenging to infer the functional consequences of common variant associations 3 beyond cases where protein-altering variants have been directly implicated. Protein-truncating variants (PTVs), also commonly referred to as loss-of-function (LoF) variants 4 as they often result in a non-functional or unstable gene product, are generally the strongest acting genetic variants in medical genetics and, as one functional copy of the gene is removed, may often provide insight into what is achievable pharmacologically via inhibition of the product of the gene 5 . Thus, identifying PTVs that are demonstrated to lead to loss of gene function and confer protection from disease hold particular promise for identifying therapeutic targets [6] [7] [8] [9] .
Screen Sequencing
We conducted targeted sequencing of the exons of 759 protein-coding genes in regions harboring common variants associated to IBD 10, 11 in 917 healthy controls, 887 individuals with UC (cases), and 1204 individuals with CD (cases) from the NIDDK IBD Genetics Consortium (North American clinical samples of European descent). We jointly analyzed these data with sequencing data from the same genes taken from an exome sequencing data set of Finnish individuals: 508 with UC, 238 with CD, and 8124 Finnish reference samples sequenced within Sequencing Initiative Suomi (SISu) project (www.sisuproject.fi) 12 . Across this targeted gene set, we discovered 81 PTVs found in 2 or more individuals ( Supplementary Table 1 ) and used a Cochran-Mantel-Haenszel chi-squared test to scan for protective variants with two strata corresponding to the two cohorts. The test for association was run based on the phenotype (CD, UC or IBD) indicated by the common variant association in the region 13 (that is, truncating variants in a gene associated only to CD such as at NOD2 would be tested for CD vs. control association). We identified three putatively protective PTVs with a P value < 0.05: (1) a previously published low-frequency variant in CARD9 (c.IVS11+1G>C) located on the donor site of exon 11 which disrupts splicing (P = 0.04) 7,14 ; (2) a frameshift indel in ABCA7 (P = 0.02); and (3) a premature stop gain variant (p.R179X) in RNF186 with signal of association (P = 0.02) to ulcerative colitis. As the CARD9 result was a well-established protective association, and ABCA7 contained four additional PTVs that did not appear protective (combined odds ratio was greater than 1 and a signal of mixture of risk and protective effects would require a sequencing follow-up strategy), we focused specifically on follow-up work to confirm or refute the association of the RNF186 nonsense variant (the only PTV detected in RNF186 in either sequence data set).
Replication
Replication genotype data obtained in 8,300 ulcerative colitis patients and 21,662 controls from US, Canada, UK, Sweden, Belgium, Germany, Netherlands and Italy provided strong support that the premature stop-gain allele, p.R179X, confers protection against ulcerative colitis (P = 0.0028, OR = 0.36 [95% CI=0.19-0.71]). Cluster plots from all genotyping assays were manually inspected to insure consistent high quality across all experimental modalities used to assess this variant (Supplementary figures 1,2).
Further evidence of replication was seen in whole-genome sequence data followed by imputation collected by deCODE Genetics 15, 16 , in which a set of 1,453 Icelandic patients with UC were compared to a very large population sample (n=264,744) and a consistent strong protection (P = 5.0x10 -4 , OR = 0.30 [95% CI=0.15-0.59], imputation information of 0.99; overall replication P = 8.69x10 -6 , OR = 0.33 [0.20-0.55]) was observed between the truncating allele and the disease ( In Iceland, the sequencing of a large fraction of the population followed by imputation assisted by long range phasing in around 150 thousands individuals allow us to identify homozygotes for rare loss-of-function variants 17 . We find 8 individuals homozygous for the 179X allele (MAF=0.78%), the oldest reached the age of 70 (still alive) and one of the eight died (age 62), consistent with Hardy-Weinberg expectation (n=9.1). There was no significant association of the homozygous genotype with a decreased lifespan or fertility (number of children). Given the lower frequency in other populations, no homozygous individual was expected and/or detected in the Exome Aggregation Consortium (ExAC) nor in the remaining set of individuals in this study. Together this indicates that having 2 copies with a stop gained in RNF186 is compatible with life, reproduction and aging -and importantly does not highlight severe medical consequences that would be of obvious concern in developing a therapeutic to mimic the effect of this allele.
The combined significance across all samples tested is P = 6.89x10 -7 (OR = 0.30 [95% CI=0.19-0.50]) -considering we advanced only one variant to follow-up study, the replication p-value of 8.7x10 -6 is unequivocally significant and would have been significant even if 5000 variants were put through this follow-up, let alone all 81 that were discovered in the sequencing screen. No other PTV in RNF186 was discovered and tested in our sequencing. The gene is relatively small (227 amino acids) and R179X is by far the most common detected PTV in EXAC, more than 10 times more common than the sum of all other PTVs in the gene.
In the initial UC GWAS study the 1p36 locus had at least two non-coding independent association signals separated by recombination hotspots (rs4654903 and rs3806308; r 2 = .001, minor allele frequency = 45.5% and 47%, respectively,) that did not implicate any one of the three genes (RNF186-OTUD3-PLA2G2E) in the region 18 . Recently, a low-frequency coding variant in RNF186 (rs41264113, p.A64T, MAF=0.8%) was found to confer increased risk to ulcerative colitis (OR = 1.49 [1.17-1.90]) 14 . In the discovery and replication component of this study p.R179X was found to lie on the haplotype background of the risk allele for rs4654903 and very little correlation was observed with rs3806308 or the low-frequency coding variant p.A64T (Supplementary figure 3) . Naturally, the protective signal at p.R179X remains unchanged when corrected for the background higher risk allele rs4654903 on the haplotype it arose on (Supplementary table 2 ).
Profile of expression of RNF186 p.R179X: transcript and protein expression
RNF186, a single-exon protein-coding gene, encodes the ring finger E3 ligase which localizes at the endoplasmic reticulum (ER) and regulates ER stress-mediated apoptosis in a caspase-dependent manner 19 . To understand the functional consequences of p.R179X we integrated transcriptome and protein expression level data. First, we examined the gene expression profile of RNF186 (encoded by a single transcript isoform: ENST00000375121) across multiple tissues in the Genotype Tissue Expression (GTEx) project and identify that its highest expression is in the transverse colon (median RPKM = 17.32, n = 61) with only three other tissues having an RPKM level above 1: i) pancreas, ii) kidney cortex, and iii) the terminal ileum (Supplementary figure 4A) 20 . RNF186 protein was observed at "medium" expression levels for tissues in the gastrointestinal tract (stomach, duodenum, small intestine, appendix, colon) in the Human Protein Atlas 21 (Supplementary figure 4B ).
Functional consequences of RNF186 p.R179X: impact on transcript allele expression
We integrated allele-specific expression (ASE) data for individual carriers of p.R179X in the GTEx project. Within GTEx we identified, two individual carriers with some containing ASE data for p.R179X in transverse colon and sigmoid colon. The carriers had consistent patterns of no ASE effects (Supplementary figure 5,6) suggesting that nonsense-mediated decay (NMD) does not degrade the aberrant transcripts containing the truncating alleles and that additional functional follow-up would be necessary to determine the molecular impact of p.R179X on RNF186 5 . The gene contains one exon and is intronless, and there is prior expectation that those genes do not undergo nonsense mediated decay since this presence is reported to requite the presence of at least one intron.
Functional consequences of RNF186 p.R179X: impact on protein allele expression
Given that R179X messenger RNA was detected at levels similar to the common allele, we sought to quantify protein expression. Accordingly, we transiently transfected 293T cells with RNF186 expression constructs containing an epitope tag for detection on western blot with anti-V5 antibodies. As expected, we found that the common allele of RNF186 was efficiently expressed at the protein level, and strikingly, so was R179X ( Fig. 1 ). Although we detected expression of RNF186 regardless of the position of the V5 tag, R179X protein was detected only when the V5 tag was present on its N-terminus ( Fig. 1) . Notably, the common allele encodes two transmembrane domains and lacks an N-terminal signal peptide, which supports a model in which RNF186 N-and C-termini are present on the cytoplasmic side of membrane structures. In contrast, R179X lacks the second transmembrane domain, and must therefore position its N-and C-termini on opposite sides of the membrane. Thus, the charged C-terminal V5 tag appended to R179X cannot efficiently translocate across the ER membrane into the lumen during translation. In contrast, the N-terminal V5 tag did not impair expression of R179X, likely because it is present on the cytoplasmic side of the membrane and does not require membrane translocation. Collectively, we conclude that R179X truncation does not preclude protein expression.
This study strengthens the direct evidence for the involvement of RNF186 in ulcerative colitis risk in which a powerful allelic series, including common noncoding alleles and risk increasing p.A64T is available for further experimentation. Further supporting the medical relevance of this truncating variant, the same rare allele of the same variant coding p.R179X has been reported in Iceland to have a genome wide significant association with a modest increase in serum creatinine level (effect = 0.13 SD, P = 5.7 x10 -10 ) and a modest increase in risk of chronic kidney disease 16 . In the context of the few other established protective variants in IBD, including the coding IL23R variants (p.V362I, MAF = 1.27%, OR = 0.72 [0.63-0.83]; p.G149R, MAF = 0.45%, OR = 0.60 [0.45-.0.79]) and the splice disrupting CARD9 variant (c.IVS11+1G>C, MAF = 0.58%, OR = 0.29 [0.22-0.37]) 7 , R179X exerts a comparable protective effect. Because of the strong protective effect associated with the RNF186 protein truncating variant, studies of RNF186 inhibition and the specific action of this variant protein should be useful in understanding the mechanism by which protection to ulcerative colitis disease occurs and whether this reveals a promising therapeutic opportunity similar to that which has been realized from the example of PCSK9 and cardiovascular disease. The PRISM study data were merged with population controls of European ancestry broadly consented for biomedical studies. These controls included samples from the NIMH repository 22 , POPRES 23 , the 1000 Genomes Project 24 and controls ascertained for an age-related macular degeneration study 25 . The Italian samples were collected at the S. Giovanni Rotondo "CSS" (SGRC) Hospital in Italy. The Dutch cohort is composed of ulcerative colitis cases recruited through the Inflammatory Bowel Disease unit of the University Medical Center Groningen (Groningen), the Academic Medical Center (Amsterdam), the Leiden University Medical Center (Leiden) and the Radboud University Medical Center (Nijmegen), and of healthy controls of self-declared European ancestry from volunteers at the University Medical Center (Utrecht).
Subject ascertainment, diagnosis and validation for the UK samples are described elsewhere and are part of the UK Inflammatory Bowel Disease Genetics Consortium (UKIBDGC) 26 .
German patients were recruited either at the Department of General Internal Medicine of the Christian-Albrechts-University Kiel, the Charité University Hospital Berlin, through local outpatient services, or nationwide with the support of the German Crohn and Colitis Foundation. German healthy control individuals were obtained from the popgen biobank. Genotyping of the German cohort was performed at the Institute for Clinical Molecular Biology.
Finnish patients were recruited from Helsinki University Hospital and described in more detail previously 27, 28 .
Subject ascertainment, diagnosis and validation for a subset of the Swedish samples with ulcerative colitis 14 and without ulcerative colitis 29 are described elsewhere.
Icelandic population: A total of 1,453 individuals diagnosed with ulcerative colitis, was used in the analysis. All the cases were histologically verified, and diagnosed either by 1997 or prospectively during the period 1997 to 2009 at Landspitali, the National University Hospital of Iceland. Exome array. The Illumina HumanExome Beadchip array includes 247,870 markers focused on protein-altering variants selected from >12,000 exome and genome sequences representing multiple ethnicities and complex traits. Nonsynonymous variants had to be observed three or more times in at least two studies, splicing and stop-altering variants two or more times in at least two studies. Additional array content includes variants associated with complex traits in previous GWAS, HLA tags, ancestry informative markers, markers for identity-by-descent estimation, and random synonymous SNPs. We focused on variant exm26442, which was the only PTV in the targeted sequencing data set that was also in the exome array and had a P value < 0.05 in the screening component of the study. Samples in the targeted sequencing data set were excluded from the exome array analysis.
NIDDK NHGRI targeted sequencing
UK sequencing. The UKIBDGC sequenced low coverage whole genomes of 1767 UC patients from our nationwide cohort (median depth 2X) and compared them to 3652 population controls from the UK10K project (median depth 7X). Samples were jointly called using samtools 30 , and subjected to two rounds of genotype improvement using BEAGLE 31 . Genotype count for R179X from exome sequencing data in 161 additional UK ulcerative colitis patients with severe adverse drug response to common IBD drugs were included.
Replication in Iceland population
The Iceland population data has been extended following the step below 15, 32 .
Sequencing was performed using three different types of Illumina sequencing instruments. a) Standard TruSeq DNA library preparation method. Illumina GAIIx and/or HiSeq 2000 sequencers (n=5582). b) TruSeq DNA PCR-free library preparation method. Illumina HiSeq 2500 sequencers (n=2315). c) TruSeq Nano DNA library preparation method. Illumina HiSeq X sequencers (n=556).
Genotyping and imputation methods and the association analysis method in the Icelandic samples were essentially as previously described 15 with some modifications that are described here. In short, we sequenced the whole genomes of 8,453 Icelanders using Illumina technology to a mean depth of at least 10X (median 32X). SNPs and indels were identified and their genotypes determined using joint calling with the Genome Analysis Toolkit HaplotypeCaller (GATK version 3.3.0) 33 . Genotype calls were improved by using information about haplotype sharing, taking advantage of the fact that all the sequenced individuals had also been chip-typed and long range phased. The sequence variants identified in the 8,453 sequenced Icelanders were imputed into 150,656 Icelanders who had been genotyped with various Illumina SNP chips and their genotypes phased using long-range phasing 34, 35 .
Allele specific expression data for R179X carriers. The primary and processed data used to generate the ASE analyses presented in this manuscript are available in the following locations: All primary sequence and clinical data files, and any other protected data, are deposited in and available from the database of Genotypes and Phenotypes (www.ncbi.nlm.nih.gov/gap) (phs000424.v6.p1). Tissues with at least eight reads of data are presented.
Rnf186 protein expression and localization for R179X carriers.
Plasmids. cDNA encoding human RNF186 was obtained from The Genetic Perturbation Platform (GPP, Broad Institute) and cloned by Gibson assembly into the pLX_TRC307 expression construct. Sequences encoding V5 and Flag tags were appended to oligonucleotides for PCR amplification of RNF186.
Biochemistry. 293T cells (ATCC) were transfected with RNF186 expression constructs by means of Lipofectamine 2000 (Life Technologies) as indicated by the

